Rick,
Sure has been dead around here lately. The Inamed conference call was very positive toward ATIS, and the last few days have finally seen some upward movement of ATIS, albeit not on huge volume. Could involve S&N's move with another company they had a good sized stake in, or could be many other things. Looked like on Thompson today that there were 100,000 institutional shares purchased today in 2 50,000 share deals. Coming to a fork in the road here technically, as 3.56 is where S&N recently put their 10 million....so this is obviously a point of resistance. I would expect bigger volume if this is truly a sign of things to come with any noted fundamental progress. The questions now are still open to all as to the timing of the study(is sept/oct submission to the fda still likely, etc?).
Anyway, for what it's worth, Inamed spoke of 5 licensed ATIS products that they feel have big potential, with a 3-5 year timeframe. They gave one example of using human collagen for lumpectomies to avoid dimpling with breast reconstruction(over 300,000 done per year in the usa). Okay, done with the typing for the moment. Anyone else still out there?
Regards,
Marshall |
